HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Liabilities and Shareholders Equity (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Liabilities and Shareholders Equity came in at $1.7 billion in Q2 2026, down 2.22% year-over-year from $1.8 billion in Q2 2025, and down 0.95% quarter-over-quarter from $1.8 billion in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 2.22% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $5.3 billion, a 73.39% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, changed N/A from the prior year.
  • Liabilities and Shareholders Equity was $1.7 billion for Q2 2026 at HUTCHMED (China), down from $1.8 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $1.8 billion in Q2 2025 and troughed at $1.0 billion in Q4 2022.
  • A 5-year average of $1.4 billion and a median of $1.3 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity declined 25.0% in 2022 and soared 40.85% in 2025, its largest moves.
  • Over 5 years, Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then rose by 26.04% to $1.3 billion in 2023, then retreated by 2.82% to $1.3 billion in 2024, then soared by 39.04% to $1.8 billion in 2025, then decreased by 0.95% to $1.7 billion in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $1.7 billion (Q2 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Amgen 210.97 Bn 196.98 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 180.98 Bn 177.80 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 132.09 Bn 124.24 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 82.56 Bn 74.57 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 61.71 Bn 56.53 Bn 1.37 Bn 10.03 Bn
6 Moderna 54.60 Bn 49.46 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 34.02 Bn 30.71 Bn 992.69 Mn 5.56 Bn
8 Biogen 31.25 Bn 29.97 Bn 1.96 Bn 32.09 Bn
9 Roivant Sciences 29.76 Bn 29.76 Bn 1.16 Mn 5.31 Bn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 1.74 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.74 Bn
Dec 31, 2025 1.75 Bn
Jun 30, 2025 1.78 Bn
Jun 30, 2024 1.26 Bn
Jun 30, 2023 1.30 Bn
Dec 31, 2022 1.03 Bn
Jun 30, 2022 1.19 Bn
Dec 31, 2021 1.37 Bn
Jun 30, 2021 1.27 Bn
Mar 31, 2021 693.12 Mn
Dec 31, 2020 724.12 Mn
Jun 30, 2020 525.56 Mn
Dec 31, 2019 465.12 Mn
Sep 30, 2019 454.09 Mn
Jun 30, 2019 495.21 Mn
Mar 31, 2019 539.30 Mn
Dec 31, 2018 532.12 Mn
Jun 30, 2018 577.94 Mn
Dec 31, 2017 597.93 Mn
Jun 30, 2017 344.70 Mn